复宏汉霖(2696.HK):全球化创新极具特色 国际化BIOPHARMA扬帆起航

招商证券
12 Mar

复宏汉霖作为国际化Biopharma,其差异化管线具备全球竞争力,具有挑战当前标准治疗的潜力。同时公司全球化已经进入实质性发展阶段,PD-1 及生物类似药持续出海可期。首次覆盖,给予“强烈推荐”投资评级。差异化创新管线具备全球竞争力,具备挑战当前治疗标准的潜力。复宏汉霖创新研发管线极具特色:1)HLX10(PD-1 单抗)显著改善1 线mCRC(复发或无法根治切除的结直肠癌)患者生存期,有望成为1...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10